Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis
- 23 February 2016
- journal article
- research article
- Published by Springer Nature in Molecular and Cellular Biochemistry
- Vol. 414 (1-2) , 85-94
Abstract
Studies have suggested that abnormal expression of complement regulatory proteins and cytokines contribute significantly to the path-physiology of rheumatoid arthritis. In this context, Decay accelerating factor (DAF) a complement regulatory protein is gaining increased attention. With the notion that immune effecter mechanisms are all interlinked and circulating peripheral blood mononuclear cells (PBMCs) should have a role in a systemic disease like rheumatoid arthritis, we studied the modulation and significance of PBMC-DAF and cytokines in RA. Seventy-five RA patients and 75 healthy controls were recruited. Expression of DAF and cytokines (IFN-γ, IL-17A and IL-10) in the PBMCs of patients and controls was determined. Correlations among DAF, cytokines, and disease activity were evaluated by standard statistical methods. The effect of IFN-γ, IL-17A, and IL-10 on the expression of DAF in patients and controls was studied in vitro. Expression of PBMC-DAF declined in patients both at mRNA and surface level and correlated negatively with the disease activity. Expression of IFN-γ also declined in patients but correlated positively with DAF and negatively with disease activity. Expression of IL-17A and IL-10 was higher in patients. The levels correlated positively with disease activity and negatively with DAF both in patients and controls. In vitro studies indicated that IFN-γ up-regulated DAF expression in PBMCs, whereas IL-17A and IL-10 had negative effect on the same. The decline in the PBMC-DAF is a contributing factor in manifestations of RA. Cytokine environment contributes to this decline. These findings brought novel insights into the complement-cytokine axis in the path-physiology of RA.Keywords
Funding Information
- University Grants Commission
This publication has 53 references indexed in Scilit:
- Targeting interleukin-17 in patients with active rheumatoid arthritis: rationale and clinical potentialTherapeutic Advances in Musculoskeletal Disease, 2013
- Interferon Gamma Suppresses Collagen-Induced Arthritis by Regulation of Th17 through the Induction of Indoleamine-2,3-DeoxygenasePLOS ONE, 2013
- Decreased PERP Expression on Peripheral Blood Mononuclear Cells from Patient with Rheumatoid Arthritis Negatively Correlates with Disease ActivityJournal of Immunology Research, 2013
- Combined anti-tumor necrosis factor-α therapy and DMARD therapy in rheumatoid arthritis patients reduces inflammatory gene expression in whole blood compared to DMARD therapy aloneFrontiers in Immunology, 2012
- Interleukin-10 Signaling in Regulatory T Cells Is Required for Suppression of Th17 Cell-Mediated InflammationImmunity, 2011
- Circulating Cytokine Profiles and Their Relationships with Autoantibodies, Acute Phase Reactants, and Disease Activity in Patients with Rheumatoid ArthritisMediators of Inflammation, 2010
- Modulation of CR1 transcript in systemic lupus erythematosus (SLE) by IFN-γ and immune complexMolecular Immunology, 2007
- Epidemiological Aspects of Rheumatoid ArthritisAnnals of the New York Academy of Sciences, 2006
- Coupling complement regulators to immunoglobulin domains generates effective anti-complement reagents with extended half-lifein vivoClinical and Experimental Immunology, 2002
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988